.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The evidence for intradetrusor botulinum toxin in neurogenic bladder is particularly relevant to neurological patients who remain symptomatic despite oral therapy. Randomized data in multiple sclerosis and spinal cord injury demonstrate meaningful reductions in urinary incontinence and improved quality-of-life outcomes after onabotulinumtoxinA injections. The therapeutic effect is achieved locally within the detrusor, offering an alternative when antimuscarinic treatment is insufficient or poorly tolerated. The principal practical issue is that detrusor relaxation can increase post-void residuals and urinary retention, so clinicians must assess emptying and be prepared to teach intermittent catheterisation when required. The treatment is also temporary and generally needs repeat procedures. For HCPs, neurogenic bladder should be managed as a chronic neurological complication rather than as an isolated urological symptom. Continence, upper urinary tract protection, sexual function, infection risk and patient independence all matter. This evidence aligns closely with IANCON's neuro-urology workshop, which covers assessment of urinary symptoms, neurogenic bladder and sexual dysfunction in neurological disease.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The evidence for intradetrusor botulinum toxin in neurogenic bladder is particularly relevant to neurological patients who remain symptomatic despite oral therapy. Randomized data in multiple sclerosis and spinal cord injury demonstrate meaningful reductions in urinary incontinence and improved quality-of-life outcomes after onabotulinumtoxinA injections. The therapeutic effect is achieved locally within the detrusor, offering an alternative when antimuscarinic treatment is insufficient or poorly tolerated. The principal practical issue is that detrusor relaxation can increase post-void residuals and urinary retention, so clinicians must assess emptying and be prepared to teach intermittent catheterisation when required. The treatment is also temporary and generally needs repeat procedures. For HCPs, neurogenic bladder should be managed as a chronic neurological complication rather than as an isolated urological symptom. Continence, upper urinary tract protection, sexual function, infection risk and patient independence all matter. This evidence aligns closely with IANCON's neuro-urology workshop, which covers assessment of urinary symptoms, neurogenic bladder and sexual dysfunction in neurological disease.
4 weeks back
A bioengineered oral nanozyme microsupplement converts pathological ROS into a protective polydopamine hydrogel shield. By curbing neutrophil extracellular traps and balancing T cells, this platform outperforms standard 5-ASA in preclinical colitis models, opening new paths for sustained remission.
3 days back
Recent research reveals that downregulating YAP1/TAZ-TEAD via Hippo signaling triggers spontaneous human trophoblast syncytialization in 3D cultures, illuminating placental biology and preeclampsia.
4 weeks back
Abdominal aortic aneurysm rupture remains a catastrophic vascular emergency. Groundbreaking research reveals that USP53 accelerates aneurysm progression by reprogramming smooth muscle cell metabolism toward aerobic glycolysis, highlighting a promising target beyond conventional diameter-based surveillance.
5 days back
A breakthrough study leverages natural language processing to accurately identify incident medication-related osteonecrosis of the jaw and track antiresorptive drug holidays from clinical narratives in electronic health records, advancing osteoporosis pharmacovigilance and dental safety.
4 days back
Recent research defines ferro-aging as a conserved iron-lipid axis driving organ decline across primates. Age-related iron dyshomeostasis stimulates ACSL4-mediated lipid peroxidation, promoting cellular senescence. Notably, vitamin C directly inhibits ACSL4, suppressing phospholipid oxidation and multi-organ decay.
5 days back
